These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24047137)

  • 21. Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: studies in Cyp1a1-/-, Cyp1a2-/-, and Cyp1a1/1a2-/- mice.
    Arlt VM; Levová K; Bárta F; Shi Z; Evans JD; Frei E; Schmeiser HH; Nebert DW; Phillips DH; Stiborová M
    Chem Res Toxicol; 2011 Oct; 24(10):1710-9. PubMed ID: 21932800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.
    Hardy KM; Strizzi L; Margaryan NV; Gupta K; Murphy GF; Scolyer RA; Hendrix MJ
    Mol Cancer Res; 2015 Apr; 13(4):670-80. PubMed ID: 25767211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism.
    Liu J; Ericksen SS; Sivaneri M; Besspiata D; Fisher CW; Szklarz GD
    Arch Biochem Biophys; 2004 Apr; 424(1):33-43. PubMed ID: 15019834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo.
    Nguyen TA; Tychopoulos M; Bichat F; Zimmermann C; Flinois JP; Diry M; Ahlberg E; Delaforge M; Corcos L; Beaune P; Dansette P; André F; de Waziers I
    Mol Pharmacol; 2008 Apr; 73(4):1122-33. PubMed ID: 18212249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP1A2 is expressed along with CYP1A1 in the human lung.
    Wei C; Caccavale RJ; Kehoe JJ; Thomas PE; Iba MM
    Cancer Lett; 2001 Sep; 171(1):113-20. PubMed ID: 11485833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of human cytochromes P450 1A1 and P450 1A2 as fused enzymes with yeast NADPH-cytochrome P450 oxidoreductase in transgenic tobacco plants.
    Shiota N; Kodama S; Inui H; Ohkawa H
    Biosci Biotechnol Biochem; 2000 Oct; 64(10):2025-33. PubMed ID: 11129571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequencing and characterization of mixed function monooxygenase genes CYP1A1 and CYP1A2 of Mink (Mustela vison) to facilitate study of dioxin-like compounds.
    Zhang X; Moore JN; Newsted JL; Hecker M; Zwiernik MJ; Jones PD; Bursian SJ; Giesy JP
    Toxicol Appl Pharmacol; 2009 Feb; 234(3):306-13. PubMed ID: 19041884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1.
    Crofts FG; Sutter TR; Strickland PT
    Carcinogenesis; 1998 Nov; 19(11):1969-73. PubMed ID: 9855011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzymatic analysis of cDNA-expressed human CYP1A1, CYP1A2, and CYP1B1 with 7-ethoxyresorufin as substrate.
    Chang TK; Waxman DJ
    Methods Mol Biol; 2006; 320():85-90. PubMed ID: 16719376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.
    Chen CS; Lin JT; Goss KA; He YA; Halpert JR; Waxman DJ
    Mol Pharmacol; 2004 May; 65(5):1278-85. PubMed ID: 15102956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954.
    Jarrom D; Jaberipour M; Guise CP; Daff S; White SA; Searle PF; Hyde EI
    Biochemistry; 2009 Aug; 48(32):7665-72. PubMed ID: 19580253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer Cells.
    Fortin S; Charest-Morin X; Turcotte V; Lauvaux C; Lacroix J; Côté MF; Gobeil S; C-Gaudreault R
    J Med Chem; 2017 Jun; 60(12):4963-4982. PubMed ID: 28535350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of sulfur dioxide inhalation on CYP1A1 and CYP1A2 in rat liver and lung.
    Qin G; Meng Z
    Toxicol Lett; 2005 Dec; 160(1):34-42. PubMed ID: 16023800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2.
    Chang TK; Chen J; Lee WB
    J Pharmacol Exp Ther; 2001 Dec; 299(3):874-82. PubMed ID: 11714871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural basis of species differences between human and experimental animal CYP1A1s in metabolism of 3,3',4,4',5-pentachlorobiphenyl.
    Yamazaki K; Suzuki M; Itoh T; Yamamoto K; Kanemitsu M; Matsumura C; Nakano T; Sakaki T; Fukami Y; Imaishi H; Inui H
    J Biochem; 2011 Apr; 149(4):487-94. PubMed ID: 21258071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumour cytochrome P450 and drug activation.
    Patterson LH; Murray GI
    Curr Pharm Des; 2002; 8(15):1335-47. PubMed ID: 12052211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2.
    Kuffel MJ; Schroeder JC; Pobst LJ; Naylor S; Reid JM; Kaufmann SH; Ames MM
    Mol Pharmacol; 2002 Jul; 62(1):143-53. PubMed ID: 12065765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine.
    Sy SK; Tang BK; Pastrakuljic A; Roberts EA; Kalow W
    Eur J Clin Pharmacol; 2001 Aug; 57(5):377-86. PubMed ID: 11599655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.